Volume 129, Issue 17 p. 2610-2612
EDITORIAL

Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient

Eda Nuhoğlu Kantarcı MD

Eda Nuhoğlu Kantarcı MD

Division of Hematology, Department of Internal Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey

Search for more papers by this author
Ece Tolgay

Ece Tolgay

School of Medicine, Uludağ University, Bursa, Turkey

Search for more papers by this author
Ahmet Emre Eşkazan MD

Corresponding Author

Ahmet Emre Eşkazan MD

Division of Hematology, Department of Internal Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey

Correspondence

Ahmet Emre Eşkazan, Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Fatih, Istanbul 34303, Turkey.

Email: [email protected]

Search for more papers by this author
First published: 03 July 2023

Abstract

In an era when tyrosine kinase inhibitors are gaining acceptance in the treatment scene of chronic-phase chronic myeloid leukemia, this editorial focuses on the search for the optimal patient-based frontline treatment option while evaluating a recent study by Tiribelli and colleagues, which is published in this issue of Cancer.

CONFLICT OF INTEREST STATEMENT

Ahmet Emre Eşkazan has received advisory board honoraria and speaker bureau honoraria from Novartis, Bristol-Myers Squibb, and Pfizer outside the present study. The other authors declare no conflicts of interest.